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Migraine is one of the most common primary headache disorders that affects 11% of
the adult population. The disease is divided into two main clinical subtypes: migraine
with aura (MA) and migraine without aura (MO). Both serotonergic and hypocretinergic
systems are involved in the migraine pathomechanism. Polymorphisms in the serotonin
transporter gene (SLC6A4) and the hypocretin receptor 1 gene (HCRTR1) may be risk
factors for migraine development due to their ability to affect serotonin and hypocretin-1
(HCRT-1) concentrations. The aim of the study was to analyze, for the first time in
the Polish population, the 5-HT transporter linked polymorphic region (5-HTTLPR) in
SLC6A4, G1222A (rs2271933) and the never before studied ∗G29A (rs41263963)
polymorphisms in the HCRTR1 gene, as well as the 5-HT and hypocretin-1 plasma
concentrations in migraine patients (MA, MO) and control subjects. The study included
123 patients that were diagnosed with migraine and 123 control subjects. Methods such
as PCR, HRMA and sequencing were used for genotyping, while 5-HT was determined
by HPLC/EC and hypocretin-1 by ELISA. No significant differences were observed
in 5-HTTLPR frequencies. The A allele of HCRTR1 G1222A occurred more often in
MO, while the GA genotype of HCRTR1 ∗G29A was more frequent among MA when
compared to control group (p < 0.05). The mean age of migraine onset in individuals
with HCRTR1 ∗G29A was 18 years old for patients with MA and 26 years old for MO
patients. The localization and type of HCRTR1 polymorphisms (G1222A—missense
variant in exon 7, ∗G29A−3′UTR variant) may predispose patients to the clinical subtype
of migraine: MO or MA, respectively. In control subjects, the short allele of 5-HTTLPR
tended to decrease the 5-HT concentration, while the A allele of HCRTR1 G1222A
decreased both 5-HT and hypocretin-1 levels. Serotonin concentrations differed in
terms of clinical features of migraine. The relation between genotypes of 5-HTTLPR,
HCRTR1 G1222A, and 5-HT concentrations may be disturbed in migraine. It seems
that HCRTR1 ∗G29A is more strongly associated with regulating the 5-HT in patients
with MA than MO, and therefore may contribute to the early age of onset for migraine.
Keywords: 5-HTTLPR, HCRTR1, 5-HT, HCRT-1, migraine
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INTRODUCTION
Migraine is a neurological disorder that occurs in two clinical
subtypes: migraine with aura (MA) and without aura (MO). The
disease affects 11% of the adult population worldwide and is three
times more common among women than men (Stovner et al.,
2007). According to the frequency of migraine attacks, migraine
is divided into an episodic and chronic form. Chronic migraine,
affecting 2% of the population, is characterized by headaches
occurring for at least 15 days in a month (Menken et al.,
2000). Migraine was classified by theWorld Health Organization
(WHO) as the third most frequent disease, as well as the seventh
cause of the decline in the quality of life, constituting a significant
medical and social problem (Vos et al., 2013). The altered quality
of life in those patients may also be explained by the fact, that
migraine, especially the chronic form, is also comorbid with
psychiatric disorders and suicidal behaviors (Friedman et al.,
2018). Serafini et al. (2012) suggested that it may be a result
of dysfunction in monoamine neurotransmission due to the
possible association with gene variants.
The novel explanation of the migraine pathomechanism
implies that the neurovascular origin in which the
trigeminovascular system (TGVS) and cortical spreading
depression (CSD) are activated. CSD is linked to migraine
aura and activation of TGVS, also by CSD, is responsible
for migraine pain. Activation of TGVS increases the level of
pro-inflammatory mediators and causes sensitization of the
pain-relevant regions of the brain. It was proposed that migraine
may be a manifestation of the central biochemical dysfunction
of pain perception (Sicuteri, 1976; Pietrobon and Striessnig,
2003). Pain perception is a complicated process mediated by
the nociceptive system in which neurotransmitters such as
serotonin (5-HT), hypocretins (HCRT), norepinephrine (NE)
and gamma-aminobutyric acid (GABA) are involved (Sicuteri,
1976; Watanabe et al., 2005; Enna and McCarson, 2006).The
trigeminovascular nociception involves the hypothalamus;
a brain area that plays a role in primary headaches, among
which migraine is the most common. The dysfunction of the
hypothalamus is presented in the circadian rhythmicity of
migraine and premonitory of attack, e.g., sleep deprivation,
yawning, changes in appetite, in wakefulness, and in autonomic
symptoms of the attack. It is proposed that HCRT may
be responsible for migraines, mainly in the early phases
of attack as hypocretinergic neurons originate from the
hypothalamus and control sleep-wake cycle, food intake,
pain modulation and regulate the autonomic system e.g., the
serotoninergic system (Holland and Goadsby, 2007; Hoffmann
et al., 2015).
Numerous studies indicate the role of the serotoninergic
system in migraine pathophysiology (Hamel, 2007; Kowalska
et al., 2016; Deen et al., 2017). During a migraine attack,
plasma 5-HT concentration is higher, and its metabolite
5-hydroxyindoleacetic acid (5-HIAA) is lower than in attack-free
periods. It is suggested that a migraine results from the
chronically low 5-HT disposition (Ferrari et al., 1989; Ferrari
and Saxena, 1993; Durham and Papapetropoulos, 2013). The
cause of imbalance in 5-HT level may be polymorphism
in 5-HT transporter (5-HTT) gene, SLC6A4. The 5-HTT
linked polymorphic region (5-HTTLPR) is the insertion/deletion
polymorphism located in the regulatory region of this gene. It
occurs in two allelic forms: the short (S) and long variant (L),
varying in length by 44 bp. Numerous studies have investigated
the relationship between SS 5-HTTLPR genotype and migraine,
but results are inconsistent, indicating its association either
with migraine (Juhasz et al., 2003a), only with MA (Borroni
et al., 2005; Marziniak et al., 2005), or MO (Gonda, 2007),
or no association (Yilmaz et al., 2001; Szilagyi et al., 2006;
Todt et al., 2006; Wieser et al., 2010). Additionally, Juhasz
et al. (2003b) analyzed the correlation between 5-HTTLPR and
5-HT only in a small group of MO patients. The correlation
between 5-HTTLPR and 5-HT in MA patients was not studied
until now. Therefore, we decided to analyze, for the first
time, the 5-HTTLPR in the Polish population of migraine
sufferers.
The functions of serotonergic neurons are regulated by
the hypocretinergic system, which consists of following
neuropeptides: hypocretin-1 (HCRT-1) and hypocretin-2
(HCRT-2), and their receptors: HCRTR1, HCRTR2. The
HCRTR1 receptor is selective for HCRT-1 (Holland and
Goadsby, 2007). A good understanding of this pathway is
important because the increased HCRT neural activity was
observed in response to persistent pain and stress. HCRT-1
and HCRTR1 were found in the brain regions responsible
for nociceptive processing: periaqueductal gray rostral ventral
medulla, and in the lamina I of the spinal cord. Moreover,
higher sensitivity to pain after peripheral inflammation and
reduced stress-induced analgesia were found in HCRT-knockout
mice as compared to control animals. Additionally, central
administration of HCRT-1 in acute and persistent pain showed
an analgesic effect. These findings suggest that HCRT neurons
may inhibit pain transmission by themselves or by activating
the descending pain inhibitory system (Ida et al., 2000; Bingham
et al., 2001; Yamamoto et al., 2002; Cheng et al., 2003; Watanabe
et al., 2005). The genetic study of Rainero et al. (2011b) suggested
that non-synonymous G1222A polymorphism in HCRTR1 gene
is a risk factor for MO, but does not modify the clinical features
of the disease. They did not focus on the possible association
between the HCRTR1 G1222A genotypes and HCRT plasma
levels. Until now, the HCRTR1 ∗G29A polymorphism was not
analyzed previously in any disease. According to our preliminary
study, performed on a group of 34 migraine patients, both
5-HTTLPR and HCRTR1 G1222A polymorphisms may be
associated with 5-HT and HCRT-1 concentrations (Kowalska
et al., 2016). It was the first study in which the correlations
between 5-HT and HCRT in combination with genetic analysis
were analyzed. Thus, we continued the study on a bigger group of
patients and analyzed the new HCRTR1 ∗G29A polymorphism.
The aim of the study was to investigate the relationship
between 5-HTTLPR and HCRTR1 (G1222A, ∗G29A)
polymorphisms and the concentration of 5-HT and HCRT-1 in
plasma of MA, MO patients, and the control group.
We believe that these polymorphisms may be risk factors for
MA andMO andmay be associated with the lower concentration
of 5-HT and HCRT-1.
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MATERIALS AND METHODS
Patients and Controls
The study was performed in 246 individuals, both migraine
patients and control subjects.
Between 2015 and 2017, a total of 123 migraine patients
(112 females, 11 males; mean age ± SD: 40 ± 14 years)
were selected for the study from the Department of Neurology
at Poznan University of Medical Sciences (PUMS) and the
neurology clinic. The diagnosis of migraine was performed
according to the ICHD-3 criteria (Headache Classification
Committee of the International Headache Society (IHS), 2003),
by an experienced neurologist. Forty-nine patients fulfilled the
diagnostic criteria for MA and 74 for MO.
The control group consisted of 123, sex and age-matched
healthy subjects (112 females, 11 males, mean age ± SD:
39 ± 14 years). These participants were recruited via
advertisements throughout PUMS. All individuals (patients
and controls) were from the Polish Caucasian population.
None of them were suffering from psychiatric or any other
neurological disorders.
The clinical features of migraine: frequency of attacks and
duration of a headache, were scored on a scale of 1–3, designed by
Laboratory of Neurobiology PUMS. For frequency of a headache:
1–less than one attack per month, 2–one or two per month,
3–more than two per month. For the duration of a headache:
1–less than 24 h, 2–from 24 h to 48 h, 3–more than 48 h.
This study was carried out in accordance with the
recommendations of the national legislation and the Code
of Ethical Principles for Medical Research Involving Human
Subjects of the World Medical Association. The protocol was
approved by the Local Bioethical Committee of PUMS (no.
931/14 with an extension no. 993/17). All subjects gave written
informed consents in accordance with the Declaration of
Helsinki.
The blood was collected in the headache-free period. All
samples were blinded to avoid bias. Genotyping was performed
in all patients (treated and untreated) and control subjects.
Individuals treated with triptans, antiepileptic and antidepressant
drugs were excluded from biochemical studies (7 MA and 5 MO
patients).
Genetic Analyses
Genomic DNA was extracted using Genomic Micro AX
Blood Gravity isolation kit (A&A Biotechnology, Poland) and
stored at−80◦C.
Polymerase chain reaction (PCR) of 5-HTTLPR was
carried out using the following primers: 5′-GGCGT
TGCCGCTCTGAATGC-3′ (forward) and 5′-GAGGGACT
GAGCTGGACAACCAC-3′ (reverse) in reaction mixtures with
a total volume of 15 µl, containing 45 ng genomic DNA, 10 pM
of each primer, 4.5 nM dNTP, 5% DMSO, 1.125 U Hi-Fi Taq
polymerase and 10× buffer for Hi-Fi Taq polymerase (Novazym,
Poland). Temperatures were 63◦C for 30 s for annealing and
72◦C for 60 s for the extension. The 5-HTTLPR genotypes were
identified by electrophoresis in 2% agarose gel, S allele had
484 bp, while L had 528 bp.
High-resolution melting analysis (HRMA) was used to
genotype missense single nucleotide polymorphism (SNP)
G1222A (rs2271933) in the exon 7 and ∗G29A (rs41263963) SNP
in 3′UTR region of the HCRTR1 gene, using LightCycler 480
Real-Time PCR System (Roche, USA). At the beginning, when
we started analyzing the G1222A polymorphism of HCRTR1
gene, we found that some patients had another polymorphism:
∗G29A. Therefore, we designed new primers to analyze
∗G29A alone without the effect of the G1222A polymorphism
on the melt curve. The primers for HRMA were designed
using online Primer3Plus software based on the published
genome sequence of the HCRTR1 gene and had the following
sequences: G1222A: 5′-TCTCTGAAGGCCCCTAGTCC-3′
(forward) and 5′-GACTGAAGCCACAGCCTTTC-3′ (reverse);
∗G29A: 5′-CTCACCAGCGTCACCACA-3′ (forward) and
5′-CTCACATCAACCCTGCTTAGG-3′ (reverse). The results
of HRMA were confirmed by sequencing in the forward and
reverse directions using the 3130xl Genetic Analyzer (Applied
Biosystems HITACHI, USA) in the independent unit. The reads
were aligned to the human reference genome with BioEdit
Software (Tom Hall Ibis Biosciences, Canada) separately by two
investigators. The intercalating dye used was EvaGreen, and
the reaction mixture with a total volume of 10 µl consisted of
1× SsoFastTM EvaGreenr Supermix (BioRad, USA), 250 nM of
each primer and 15 or 30 ng genomic DNA (G1222A or ∗G29A).
The PCR reaction was performed as follows: initial denaturation
for the 30 s at 95◦C, followed by 45 cycles at 95◦C for 10 s and
62◦C for 30 or 20 s (G122A or ∗G29A). After PCR, samples were
heated to 95◦C for 30 s and then the melting was performed
from 60◦C to 95◦C at the rate of 0.2◦C/3 s or 0.3◦C/2 s (G1222A
or ∗G29A).
Biochemical Analyses
The plasma 5-HT concentration was determined by
high-pressure liquid chromatography coupled with
electrochemical detection (HPLC/EC). The 0.1 M acetate
buffer, pH 5.0 was added to the plasma samples and 5-HT
standards (Sigma-Aldrich, USA) in a ratio of 1:3 and mixed.
The samples were deproteinized with 8 M HClO4 in a ratio of
10:1 and fed to a HPLC/EC system. The analysis was carried out
on a Thermo Hypersil BDS C18 (250 mm × 4.6 mm × 5 µm)
column (Germany), in isocratic conditions using a mobile phase
of 10 mM phosphate buffer, pH 5.0 containing 10% methanol.
The system was controlled, and data was collected and processed
using Chromeleon software (Dionex, Germany).
The plasma concentration of HCRT-1 was evaluated using
commercially available enzyme-linked immunoassay (ELISA)
kit (Wuhan EIAlab Science Co., China) according to the
manufacturer’s protocol (inter- and intra-assay coefficients of
variability amounted: ≤8.5% and ≤6.7%, respectively).
Statistics
The sample size was calculated with the acceptable level
of alpha error α < 0.05 and the estimation error of
0.09 on the assumption that 11% of Wielkopolska Voivodeship
population suffers from migraine. The sample size was fixed at
119 patients.
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The analyses were performed for MA and MO patients both
separately and combined. The Fisher’s exact test, Chi-square
test and odds ratio (OR) with 95% confidence intervals (95%
CI) were applied for analysis of the distribution of alleles
and genotypes. Hardy-Weinberg equilibrium was verified for
all the polymorphisms in MA, MO and control groups using
Chi-square test. The normality of the data (5-HT, HCRT-1)
distributions was checked using the Shapiro-Wilk test (if
the sample size were 50 or less) and Kolgomorov-Smirnow
(if the sample size were larger than 50). Analysis of the
homogeneity of variance was carried out using the Levene test.
The differences in 5-HT or HCRT-1 levels between groups with
each genotype were tested by Kruskal-Wallis tests (in the case
of three groups) and Mann-Whitney test (in the case of two
groups). Correlations between 5-HT and HCRT-1 were tested
using Spearman’s rank test. GraphPad (Instant) and Statistica
12.0 for Windows (StatSoft, USA) were used to evaluate the
results of the study. Two-tailed p < 0.05 were considered
statistically significant in the case of two groups. Considering
the potential false positive rate incurred by multiple comparisons
of several gene associations in controls and two patient groups,
we applied the Bonferroni correction method to adjust the
p-value.
RESULTS
The MA and MO groups differed regarding the duration
of migraine history, mean number of attacks per month
and duration of the attacks. The majority of MA patients
suffer from migraine for more years, experience fewer attacks,
which last shorter than migraine attacks in MO group
(Table 1).
Genetic Analyses
None of the analyzed polymorphisms showed significant
deviation from Hardy-Weinberg equilibrium in either MA, MO
TABLE 1 | Clinical description of the migraine patients.
Characteristic MA MO
Mean age at interview (years) 39 ± 14 40 ± 15
Duration of migraine history (years):
<5 10.2% 11.1%
5–10 20.4% 61.1%
>10 69.4% 27.8%
Mean number of attacks per month:
<1 33.3% 12.2%
1–2 47.9% 48.6%
>2 18.8% 39.2%
Mean duration of attacks (hours):
<24 34.0% 16.7%
24–48 34.0% 52.8%
>48 32.0% 30.5%
Unilateral pain 93.5% 84.7%
Pulsating pain 73.3% 74.0%
Nausea 91.3% 90.4%
Vomiting 73.9% 52.1%
Photophobia 89.1% 91.9%
Phonophobia 77.8% 82.4%
Osmophobia 72.7% 68.1%
or control subjects. In the control group, the minor allele
frequency (MAF) for analyzed nucleotide variants was at least
3.3%. The power to detect a disease susceptibility locus was
between 88% and 99%.
No statistical differences were found in frequencies of
5-HTTLPR (Table 2). However, the genotype and allele
frequencies of the analyzed polymorphisms in HCRTR1 varied
between MA, MO patients, and healthy controls. The A allele
of HCRTR1 G1222A was more frequent in the MO group than
in the control group (p = 0.0414, Chi-square test), while GA
genotype of HCRTR1 ∗G29A was more common in the MA
group compared to the control group (p = 0.0453, Fisher’s
exact test). The differences in HCRTR1 G1222A and ∗G29A
frequencies were not statistically significant when we considered
MA and MO patients together.
None of the alleles were associated with increased migraine
risk, although the A allele of HCRTR1 G1222A (p = 0.0574) and
the A allele of HCRTR1 ∗G29A (p = 0.0647) approached the
borderline of significance (Table 3). Interestingly, the majority
of MA individuals with GA HCRTR1 ∗G29A shared the same
clinical feature: the early onset of the disease: migraine started
before the age of 18. The mean age of onset of the disease in GA
carriers of HCRTR1 ∗G29A for MO was 26 years. None of the
examined subjects had the AA genotype of HCRTR1 ∗G29A.
We also analyzed the clinical features of migraine in the
presence of the S allele of 5-HTTLPRR and the A allele
of HCRTR1 G1222A polymorphisms. The average migraine
TABLE 2 | Genotype and allele frequencies of 5-HTT linked polymorphic region
(5-HTTLPR) and hypocretin receptor 1 gene (HCRTR1) G1222A, ∗G29A
polymorphisms.
Controls MA MO Migraine patients
(MA+MO)
5-HTTLPR
Genotypes:
SS (%) 12 (9.7) 5 (10.2) 12 (16.2) 17 (13.8)
SL (%) 59 (48.0) 29 (59.2) 35 (47.3) 64 (52.0)
LL (%) 52 (42.3) 15 (30.6) 27 (36.5) 42 (34.2)
Alleles:
S (%) 83 (33.7) 39 (39.8) 59 (39.9) 98 (39.8)
L (%) 163 (66.3) 59 (60.2) 89 (60.1) 148 (60.2)
HCRTR1 G1222A
Genotypes:
GG (%) 43 (35.0) 14 (28.6) 14 (18.9)∗ 28 (22.8)
GA (%) 58 (47.1) 24 (49.0) 43 (58.1)∗ 67 (54.4)
AA (%) 22 (17.9) 11 (22.4) 17 (23.0) 28 (22.8)
Alleles:
G (%) 144 (58.5) 52 (53.1) 71 (48.0) 123 (50.0)
A (%) 102 (41.5) 46 (46.9) 77 (52.0)∗ 123 (50.0)
HCRTR1 ∗G29A
Genotypes:
GG (%) 115 (93.5) 41 (83.7)∗ 65 (87.8) 106 (86.2)
GA (%) 8 (6.5) 8 (16.3)∗ 9 (12.2) 17 (13.8)
AA (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Alleles:
G (%) 238 (96.7) 90 (91.8) 139 (93.9) 229 (93.1)
A (%) 8 (3.3) 8 (8.2) 9 (6.1) 17 (6.9)
MA, migraine with aura, MO, migraine without aura. ∗p < 0.05 compared to
controls, Fisher’s exact test or Chi-square test, as appropriate.
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TABLE 3 | Genotypic and allelic distribution of 5-HTTLPR and HCRTR1 G1222A,
∗G29A polymorphisms in migraine patients (MA+MO) compare to control
subjects.
Chi-square p OR 95% CI
5-HTTLPR
Alleles:
S vs. L 1.967 0.1608 1.30 0.90–1.88
Genotypes:
SS vs. LL 1.725 0.1890 1.75 0.76–4.08
SL vs. LL 1.152 0.2830 1.34 0.78–2.30
SS vs. SL 0.409 0.5225 1.31 0.58–2.96
HCRTR1 G1222A
Alleles:
A vs. G 3.612 0.0574 1.00 0.69–1.45
Genotypes:
AA vs. GG 3.238 0.0720 1.96 0.94–4.07
GA vs. GG 3.637 0.0565 2.16 1.17–4.00
AA vs. GA 0.083 0.7735 1.10 0.57–2.13
HCRTR1 ∗G29A
Alleles:
A vs. G 3.413 0.0647 2.21 0.94–5.22
Genotypes:
GA vs. GG 3.607 0.0576 2.31 0.96–5.56
attack frequency and the average duration of the headache
between group S (SS and SL genotype) and group L (LL
genotype) of 5-HTTLPR in MA and MO patients showed no
statistical differences. Similarly, the results of the analysis of
migraine frequency and length of the headache in group A
(AA and GA) and group G (GG) of HCRTR1 G1222A were
negative.
Biochemical Analyses
The significantly higher 5-HT plasma concentrationwas found in
MA patients as compared to MO patients (p = 0.0308, Kruskal-
Wallis test) or control subjects (p = 0.0369, Mann-Whitney
test). No significant changes were observed in the HCRT-1
concentration (Table 4). The correlation between 5-HT and
HCRT-1 occurred only in the control group (Spearman’s
coefficient Rs = +0.4049, p = 0.010).
We also correlated 5-HT and HCRT-1 concentrations with
the clinical features of migraine. The MA and MO patients
were divided into smaller groups according to the duration of
migraine history, the average length of migraine attack and
an average number of attacks per month. The 5-HT level was
higher in patients with longer migraine history. The 5-HT
concentration was increased in individuals suffering from MA
between 5–10 years as compared to control and MO patients
(p = 0.0212, Kruskal-Wallis test). The level of biochemical
markers differed with the average length of the attacks. The
lowest 5-HT concentration was observed in patients (both MA
and MO) with attacks longer than 48 h. Higher HCRT-1
concentration was characterized by shorter migraine attacks, but
TABLE 4 | 5-HT and HCRT-1 concentration in MA, MO, both migraine patients (MA+MO) and controls.
Controls MA MO Migraine patients p(I) p(II)
5-HT 0.095 ± 0.090; 0.123 ± 0.0941,2; 0.084 ± 0.086; 0.098 ± 0.091; 0.03081 0.03692
[µg/mL] 0.078; 0.0121; 0.068; 0.073; 0.3084
0.029, 0.140 0.053, 0.170 0.018, 0.110 0.023, 0.151 0.7240
HCRT-1 664.1 ± 406.0; 648.1 ± 341.4; 715.9 ± 358.9; 684.4 ± 349.6; 0.7273 0.9900
[pg/mL] 542.10; 592.65; 678.75; 609.90; 0.4779
319.8, 1007.1 329.35, 962.28 384.88, 1058.88 357.85, 1033.53 0.6405
The values in each cell represent: mean ± standard deviation; median; quartile 1, and quartile 3. MA, migraine with aura, MO, migraine without aura, 5-HT, serotonin,
HCRT-1, hypocretin-1. Kruskal-Wallis test (p I) and Mann-Whitney test (p II). Statistical significance at p < 0.05: 1between MA and MO (p I); 2between MA and controls
(p II). Spearman’s coefficient, Rs = +0.4049, p = 0.010 between 5-HT and HCRT-1 in control group.
TABLE 5 | 5-HT concentration in MA, MO, both migraine patients (MA+MO) and control subjects regarding different genotypes of 5-HTTLPR, HCRTR1 G1222A,
and ∗G29A.
Controls MA MO Migraine patients p (I) p (II)
5-HTTLPR
SS 0.057 ± 0.053 0.165 ± 0.0351 0.086 ± 0.104 0.111 ± 0.095 0.03671 0.1519
SL 0.092 ± 0.098 0.122 ± 0.095 0.093 ± 0.076 0.106 ± 0.086 0.2049 0.1724
LL 0.106 ± 0.087 0.110 ± 0.104 0.072 ± 0.093 0.084 ± 0.097 0.0716 0.0951
HCRTR1 G1222A
GG 0.101 ± 0.102 0.140 ± 0.0572 0.074 ± 0.078 0.106 ± 0.075 0.03752 0.4233
GA 0.094 ± 0.085 0.130 ± 0.109 0.083 ± 0.094 0.098 ± 0.100 0.1298 0.8161
AA 0.083 ± 0.077 0.093 ± 0.095 0.091 ± 0.075 0.092 ± 0.083 0.8636 0.6301
HCRTR1 ∗G29A
GG 0.095 ± 0.089 0.137 ± 0.0943,4 0.084 ± 0.089 0.103 ± 0.094 0.00433,4 0.6078
GA 0.083 ± 0.111 0.062 ± 0.066 0.080 ± 0.064 0.070 ± 0.063 0.7965 0.8366
The values in each cell represent: mean ± standard deviation. MA, migraine with aura, MO, migraine without aura. Kruskal-Wallis test (p I) and Mann-Whitney test (p II).
Statistical significance at p < 0.05:1between MA and controls (p I); 2between MA and MO (p I); Statistical significance at p < 0.01: 3between MA and controls, 4between
MA and MO (p I).
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TABLE 6 | HCRT-1 concentration in MA, MO, both migraine patients (MA, MO) and control subjects regarding different genotypes of 5-HTTLPR, HCRTR1 G1222A and
∗G29A.
Controls MA MO Migraine patients p (I) p (II)
5-HTTLPR
SS 668.8 ± 337.9 354.5 ± 161.7 740.3 ± 401.0 568.9 ± 362.7 0.1910 0.5360
SL 657.9 ± 450.6 734.4 ± 370.7 793.5 ± 335.6 764.8 ± 348.7 0.7080 0.4141
LL 668.0 ± 393.0 622.3 ± 277.4 572.0 ± 370.6 594.4 ± 324.1 0.8321 0.6935
HCRTR1 G1222A
GG 752.5 ± 456.6 539.5 ± 332.7 471.2 ± 252.9 509.7 ± 293.0 0.3494 0.1551
GA 671.2 ± 389.2 715.7 ± 385.2 798.2 ± 365.0 769.1 ± 368.6 0.6266 0.4157
AA 451.5 ± 260.0 671.7 ± 278.3 683.4 ± 346.8 675.2 ± 280.0 0.2120 0.0845
HCRTR1 ∗G29A
GG 662.6 ± 402.1 656.4 ± 327.4 723.1 ± 374.2 691.7 ± 351.0 0.7681 0.6129
GA 681.5 ± 502.9 598.3 ± 472.9 677.1 ± 293.8 642.1 ± 358.8 0.9463 >0.9999
The values in each cell represent: mean ± standard deviation. MA, migraine with aura, MO, migraine without aura. Kruskal-Wallis test (p I) and Mann-Whitney test (p II).
this trend was observed only in the MO group. The increasing
trend of 5-HT and HCRT-1 concentrations was observed in MA
patients in the case of attack frequency, while in MO patients it
was not.
Genotype-Phenotype Correlations
To investigate the genotype-phenotype relationship, the plasma
5-HT and HCRT-1 levels were compared in individuals with
different genotypes of 5-HTTLPR andHCRTR1G1222A, ∗G29A
polymorphisms in the MA, MO, and control group (Tables 5, 6).
The S allele of 5-HTTLPR tended to decrease the 5-HT
concentration in the control group, while the opposite trend
was observed in MA patients. The 5-HT level was statistically
higher in MA subjects carrying SS 5-HTTLPR genotype than in
control subjects with SS genotype (p = 0.0367, Mann-Whitney
test, the power of test: 0.98). In the MO group, the 5-HT level
was the lowest in patients with LL genotype. However, the
HCRT-1 concentration was two-times lower in MA individuals
carrying SS 5-HTTLPR than in controls and MO patients with
this genotype.
The A allele of HCRTR1 G1222A tended to decrease both
5-HT and HCRT-1 concentrations in the control group. In the
migraine group (MA+MO) this decreasing trend was observed
only in 5-HT levels. However, when we divided patients into
MA and MO groups, the opposite relations occurred. In MA
patients, the A allele of HCRTR1 G1222A was associated with
lower 5-HT levels, while in MO patients with higher 5-HT levels
as compared to subjects with the G allele. The GA genotype of
HCRTR1 ∗G29Awas associated with a lower 5-HT concentration
than in individuals with GG genotype in all groups: controls,
MA, MO. The 5-HT level was higher in MA patients with
GG genotype than in control individuals with this genotype
(p = 0.0043, Mann-Whitney test, the power of the test: 0.84). The
GA genotype tended to increase the HCRT-1 concentration in
the control individuals and to decrease in MA and MO patients.
DISCUSSION
According to our knowledge this is the first study investigating
the correlation between serotonergic and hypocretinergic
systems regarding genetic studies in migraine patients. The role
of 5-HT in the migraine pathomechanism is undeniable, and
migraine is described as a chronic low 5-HT syndrome. The
reduced 5-HT and abnormal serotonergic neurotransmission
may facilitate activation of CSD and TGVS (Hamel, 2007).
Moreover, the serotonergic neurotransmission may be regulated
by HCRT, hypothalamic neuropeptides that control pain
perception and are involved in early phase of migraine
attack (Holland and Goadsby, 2007). Taken together, evidences
indicated the significant role of 5-HT and HCRT in migraine.
The disturbances in serotonergic and hypocretinergic systems
in migraine may be a consequence of polymorphisms in genes,
such as SLC6A4 and HCRTR1. For the genetic studies we chose
5-HTTLPR polymorphism of SLC6A4 and G1222A, ∗G29A SNP
of HCRTR1. We found no association between 5-HTTLPR and
migraine. However, the HCRTR1 G1222A seems to be a risk
factor for MO, while HCRTR1 ∗G29A for MA. The GA genotype
of ∗G29A may contribute to the early age of onset of migraine.
The 5-HTTLPR is a widely studied deletion/insertion
polymorphism in the SLC6A4 gene and it occurs in two alleles:
short (S) and long (L). The role of 5-HTTLPR was reported
in the development of mental diseases, pain perception and
mood disorders (Dorszewska et al., 2014). Its role in migraine
predisposition is still unclear. The studies in the Asian population
denied the association between S allele of 5-HTTLPR and
migraine (Kotani et al., 2002; Kim et al., 2005; Park et al., 2006),
while the studies in the European population are inconsistent.
The association was found in Italian (Borroni et al., 2005),
German (Marziniak et al., 2005), Hungarian (Juhasz et al.,
2003a; Gonda, 2007) populations, while other studies in German,
Austrian (Todt et al., 2006; Wieser et al., 2010), and Turkish
(Yilmaz et al., 2001) populations indicated no association with
migraine. We also found no differences in the genotype and
allele frequencies of 5-HTTLPR in the Polish population. The
divergences in European studies may result from different group
sizes, characteristics of the examined group (female and/or
male) and migraine subtypes (MA and/or MO). It needs to be
noted that two meta-analyses of 5-HTTLPR were conducted
in migraine patients and the results confirmed no association
with this disease in the European and Asian populations
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(Schürks et al., 2010; Liu et al., 2011). However, Schürks et al.
(2010) suggested that the S allele is a risk factor for migraine
among European women (OR = 2.02; 95%CI 1.24–3.28), which
underlines the mentioned ethnic differences.
A few research groups also correlated the SLC6A4 5-HTTLPR
gene with the clinical course of migraine in different populations.
In the Asian population, Kotani et al. (2002) linked SS
genotype of 5-HTTLPR with more frequent migraine attacks
than in patients with SL and LL. Whereas in the Polish
population, we found no statistical differences in migraine
frequency and headache duration between patients with S
allele (SS and SL genotype) and without (LL genotype). These
results correspond with a study performed by Wieser et al.
(2010) which showed no association of 5-HTTLPR with attack
frequency as well as no association with comorbid depression.
It seems that 5-HTTLPR does not influence the clinical course
of MA and MO.
MA andMOmay be however, associated with polymorphisms
in the HCRTR1 gene. The HCRTR1 G1222A polymorphism
is a missense variant in exon 7 leading to the substitution
of isoleucine by valine at position 408 (Ile408Val). This
polymorphism is located in the cytoplasmic tail of the receptor,
a possible binding site for G proteins. It is associated with
increased phosphorylation potential and may change the signal
transduction (Meerabux et al., 2005). The A allele of HCRTR1
G1222A occurs in 37% of the European population, while it is
more common in American (49%), African (72%) and East Asian
(76%) populations. The HCRTR1 ∗G29A is an SNP localized in
3′UTR region, and the A allele occurs in 7% of the European
population (Ensembl Database, 2017). We demonstrated that
the A allele of G1222A polymorphism was more frequent in
the MO group (52%) when compared to the control group
(42%), while the GA genotype of ∗G29A was more frequent
in the MA patients (16%) than in the control group (7%).
Statistical significances for both HCRTR1 polymorphisms were
not observed when we analyzed MA and MO patients together.
It suggests that HCRTR1 G1222A polymorphism may be a risk
factor for MO, whereas HCRTR1 ∗G29A for MA. Moreover, the
study of Rainero et al. (2011b) pointed out that the AA genotype
of HCRTR1 G1222A is a risk factor for migraine (OR 1.81, 95%
CI 1.03–3.19). When they analyzed MA and MO independently,
they found this association only in patients suffering from MO.
In our study, the A allele of this polymorphism approached
the borderline of significance as a risk factor for migraine.
We observed that the presence of the A allele of HCRTR1
G1222A (AA and GA genotype) had no significant influence on
migraine frequency and length of the headache as compared to
the GG genotype. Moreover, analysis of Rainero et al. (2011b)
showed no effects of HCRTR1 G1222A on migraine clinical
features (not only with frequency of migraine and duration of the
attack, but also with nausea, vomiting, phono- and photophobia,
pulsating pain, unilateral pain, and the age of onset of the
disease).
On the other hand, we found an effect of HCRTR1 ∗G29A
at the age of onset of MA. Our results indicated that HCRTR1
∗G29A polymorphism might be associated with MA, which
generally starts in the first two decades of life. All MA patients
with the GA ∗G29A had a positive family history of migraine.
MA female patients with the GA genotype of HCRTR1 ∗G29A
and the AA genotype of HCRTR1 G1222A developed migraines
at 30 years of life. This suggests that the AA genotype ofHCRTR1
G1222A eliminates the impact of the ∗G29A on MA early onset,
but only in women.
It is known that HCRT can modulate 5-HT action through
a direct (excitatory projections) and indirect (inhibitory
projections) pathway. Another mechanism involves the
activation of GABAergic and NE neurons by HCRT. GABAergic
neurons inhibit, while the NE neurons activate the 5-HT
neurons (Holland and Goadsby, 2007). The opposite mechanism
of action of the HCRT depends on its level: low concentrations
of HCRT-1 and HCRT-2 have the direct excitatory effect
on the 5-HT neurons, while the indirect, inhibitory effect is
characteristic for higher concentrations (Liu et al., 2002). The
NE neurons can also excite GABAergic neurons, which can
inhibit HCRT neurons. Moreover, the 5-HT inhibits the activity
of HCRT neurons (Li et al., 2016). Therefore, we correlated the
genotypes of the 5-HTTLPR, HCRTR1 G1222A and ∗G29A with
the plasma concentrations of 5-HT and HCRT-1.
We found a correlation in the control group: the S allele
of 5-HTTLPR was associated with lower 5-HT concentration
than the L allele. The cell line studies explained the impact
of 5-HTTLPR on the 5-HT level. Heils et al. (2002) indicated
that the S allele of 5-HTTLPR polymorphism is associated with
the downregulation of gene expression and two times lower
rate of 5-HTT transcription compared to the L allele. This
leads to a decrease in 5-HT uptake, thus longer serotonergic
activity and lower plasma 5-HT concentration. We showed a
lack of correlation in migraine, perhaps due to the alteration
in this mechanism in this disease. We observed a higher 5-HT
concentration in MA patients with the SS genotype than in
control subjects with this genotype. The higher 5-HT level in
the presence of the SS genotype, as compared to the SL and
LL, was also reported by the group of Juhasz et al. (2003b).
They found an association of the SS genotype and high 5-HT
concentration in the whole population (both migraine and
controls), but their migraine group consisted of only MO
patients.
We showed that changes in the 5-HT level might be
associated with polymorphisms in HCRTR1 gene, as well. The
A allele of HCRTR1 G1222A tended to decrease both 5-HT
and HCRT-1 concentrations as compared to the G allele, but
only in healthy subjects. Furthermore, we observed lower 5-HT
levels in individuals with the GA genotype of HCRTR1 ∗G29A
than in individuals with the GG in all analyzed groups (both
migraine and controls). The AA genotype of HCRTR1 G1222A
was previously linked by Rainero et al. (2011a) with a 2.5-
fold increased risk for developing major mood disorders in
comparison with the GG genotype, probably due to altered 5-HT
levels. We found the decreasing trend of 5-HT concentration in
the presence of the A allele of HCRTR1 G1222A only in MA
patients, while in MO patients the trend was increasing. No such
trend was observed in HCRT-1 concentration. It is possible that
polymorphisms in the HCRTR1 gene may alter the level of 5-HT
and indirectly HCRT-1.
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We found a positive correlation between 5-HT and HCRT-1
level only in the control group. However, the 5-HT concentration
was different in patients with various clinical features of the
disease, such as duration of migraine history, the frequency of
attacks and length of the headache. Although, plasma HCRT-1
concentration did not correlate with the duration of migraine
history and attack frequency, both in MA and MO patients. The
level of HCRT-1 was similar in MA and MO patients suffering
from longer or shorter headaches. Peres et al. (2011) studied
HCRT-1 levels in CSF of chronic migraine patients and did not
notice significant differences as compared to controls. While
Sarchielli et al. (2008) found elevated levels of HCRT-1 in CSF of
a chronic migraine and medication-overuse headache patients.
The limitation of the study is a relatively small sample size,
cross sectional study design, difficulties in identifying casual
relations due to lack of functional studies of HCRTR1 G1222A
and ∗G29A. It is not guaranteed that younger people from the
control group will not suffer from migraine in the future.
CONCLUSION
In conclusion, both serotonergic and hypocretinergic systems
are involved in the migraine pathomechanism. The 5-HTTLPR
polymorphism influences 5-HT concentrations. It seems that
G1222A and ∗G29A polymorphisms in the HCRTR1 gene may
be associated with different subtypes of migraine. The HCRTR1
G1222A polymorphism (located in exon 7) may be a risk factor
for MO, while the HCRTR1 ∗G29A (located in 3′UTR) for MA.
The strict relation between 5-HT and HCRT-1 may be altered in
migraine patients due to different genetic variants of 5-HTTLPR
and HCRTR1 G1222A or ∗G29A. Both plasma concentration
of 5-HT and localization of HCRTR1 polymorphisms may
influence the clinical presence of migraine. Further research is
needed to expand on the clinical and biological knowledge of
migraine, however, it seems that functional studies of analyzed
polymorphisms, especially HCRTR1 ∗G29A, may bring new
information about its role in the pathomechanisms of migraine.
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